<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the cost-effectiveness of posaconazole versus standard azoles in the prevention of invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> (IFI) in high-risk patients, using a pharmacoeconomic model that was adapted to a Swiss setting </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Decision tree models based on the results of two registration trials and subsequent Markov models over patient lifetimes were developed for patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and for hematopoietic stem cell transplant recipients with <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: By reducing IFIs in <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients with posaconazole prophylaxis, the contained IFI-related treatment costs more than compensated for the incremental cost of posaconazole, resulting in savings of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> 1,118 per patient </plain></SENT>
<SENT sid="3" pm="."><plain>Lifetime posaconazole prophylaxis resulted in a benefit of 0.16 life years saved per patient compared with <z:chebi fb="2" ids="46081">fluconazole</z:chebi>/<z:chebi fb="0" ids="6076">itraconazole</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with GVHD, posaconazole prophylaxis prevented 0.04 IFIs, resulting in incremental costs of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> 7,040 per patient </plain></SENT>
<SENT sid="5" pm="."><plain>Lifetime posaconazole prophylaxis resulted in a benefit of 0.15 life years saved per patient, with an incremental cost-effectiveness rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> 48,324 per life year saved </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Given the conditions of the Swiss setting, posaconazole can be considered a cost-effective early treatment strategy that increases survival in patients at risk for IFI and may have a substantial benefit for the economic burden of IFI </plain></SENT>
</text></document>